Treatment protocols for VEGF inhibitors in DME await results of major trials

VIENNA — VEGF inhibitors are now first-line therapy for center-involved diabetic macular edema with reduced vision, and treatment protocols are rapidly evolving. However, data regarding many aspects of initiation, cessation and restarting of therapy remain unknown, a speaker said at the Advanced Retinal Therapy meeting here. The Diabetic Retinopathy Clinical Research Network ( protocol trial demonstrated that Lucentis (ranibizumab, Novartis/Genentech) with deferred or prompt focal/grid laser resulted in superior visual acuity outcomes compared with laser alone, Lloyd A. Aiello, MD, said. Over 3 years, more than half of the eyes (Read more...)

Full Story →